Matthew Neal MD

Quick facts

Marketed products

• Crizanlizumab Injection · Hematology/Oncology
  Crizanlizumab is a monoclonal antibody that binds to P-selectin on the surface of platelets and endothelial cells, blocking platelet-endothelial interactions and reducing vaso-occlusive crises in sickle cell disease.
• Metformin ER
• P2Y12 · Hematology
• prophylactic heparin · Cardiovascular
  Prophylactic heparin inhibits blood clotting by enhancing the activity of antithrombin III, preventing thrombus formation.
• theraputic heparin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Matthew Neal MD portfolio CI brief
• Matthew Neal MD pipeline updates RSS